Daniel Wilkinson

Postdoc in the Fecci Lab by day…and also by night. Developing novel T cell-based therapeutics for GBM as a part of the Duke Brain Tumor Immunotherapy Program.

[Daniel Wilkinson @DSWilkinsonPhD]

Honored and excited to have work from our group and led by @EmilyCLerner included in this collection!

[Nature Cancer @NatureCancer]

✨In our #2023InReview special we provide a collection of 12 research highlights summarizing impactful papers published in 2023 and present a collection of some of our most striking @NatureCancer publications.
Check them out for some end-of-year reading.
https://t.co/6uhjoH90kG

[Immunology Podcast @ImmunoPodcast]

📣 Check out our latest episode!

Dr. @PeterFecci from @DukeMets talks about activating #Tcells to target brain tumors and his team’s work on targeting MHC-I-negative tumor cells.

Listen now: https://t.co/XmO4BowUkh

[Daniel Wilkinson @DSWilkinsonPhD]

Really interesting and exciting stuff!

[ACIR @ACIR_org]

Lerner and Woroniecka et al. showed that CD8+ T cell-dependent immunotherapies remain effective against β2m-lacking tumor cells, independent of NK cells, via CD8+ T cell-mediated cytotoxicity [...] https://t.co/XKov0jYJcL  @EmilyCLerner  @DukeMedSchool

[Bryan D. Choi MD PhD @BryanDChoi]

Extraordinary clinical responses to CAR T cell therapy for solid tumors (heavily pretreated neuroblastoma) published in @NEJM from investigators in Italy!

https://t.co/KqZKLx6LVp

[Nature Rev Immunol @NatRevImmunol]

Adaptive meets innate: CD8+ T cells kill MHC-I-negative tumour cells https://t.co/tVc2i25Sbs